Spil Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SPIL
SPIL has five approved drugs.
There are five US patents protecting SPIL drugs.
Summary for Spil
| US Patents: | 5 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 5 |
Drugs and US Patents for Spil
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spil | ASPRUZYO SPRINKLE | ranolazine | GRANULE, EXTENDED RELEASE;ORAL | 216018-001 | Feb 28, 2022 | DISCN | Yes | No | 11,510,878 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Spil | KAPSPARGO SPRINKLE | metoprolol succinate | CAPSULE, EXTENDED RELEASE;ORAL | 210428-003 | Jan 26, 2018 | RX | Yes | No | 9,700,530 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Spil | ASPRUZYO SPRINKLE | ranolazine | GRANULE, EXTENDED RELEASE;ORAL | 216018-002 | Feb 28, 2022 | DISCN | Yes | No | 11,510,878 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Spil | KAPSPARGO SPRINKLE | metoprolol succinate | CAPSULE, EXTENDED RELEASE;ORAL | 210428-001 | Jan 26, 2018 | RX | Yes | No | 9,504,655 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Spil | NIFEDIPINE | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 210838-003 | Apr 16, 2019 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Spil | AMPHOTERICIN B | amphotericin b | INJECTABLE, LIPOSOMAL;INJECTION | 212514-001 | Dec 14, 2021 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Spil Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2017523164 | ⤷ Start Trial |
| Australia | 2015287299 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2016005934 | ⤷ Start Trial |
| Mexico | 2017000384 | ⤷ Start Trial |
| Japan | 6626492 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2016005934 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Spil Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1109558 | 2008/034 | Ireland | ⤷ Start Trial | PRODUCT NAME: RANOLAZINE OR A SALT THEREOF; REGISTRATION NO/DATE: EU/1/08/462/001 20080709 |
| 1109558 | 09C0001 | France | ⤷ Start Trial | PRODUCT NAME: RANOLAZINE; REGISTRATION NO/DATE: EU/1/08/462/001-006 20080714 |
| 1411900 | 2011/016 | Ireland | ⤷ Start Trial | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105 |
| 0984957 | 2012/048 | Ireland | ⤷ Start Trial | PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812 |
| 1109558 | SPC/GB08/058 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: RANOLAZINE OR A SALT OR SOLVATE THEREOF; REGISTERED: UK EU/1/08/462/001 20080714; UK EU/1/08/462/002 20080714; UK EU/1/08/462/003 20080714; UK EU/1/08/462/004 20080714; UK EU/1/08/462/005 20080714; UK EU/1/08/462/006 20080714 |
| 0984957 | SPC/GB11/013 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
